methylprednisolone oral

P2, N=35, Recruiting, Guangzhou JOYO Pharma Co., Ltd

P2, N=75, Not yet recruiting, Tianjin Medical University General Hospital

P4, N=200, Recruiting, Emory University | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024

P2, N=1, Terminated, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N=30 --> 1 | Trial completion date: Oct 2021 --> Sep 2024 | Unknown status --> Terminated | Trial primary completion date: Oct 2021 --> Sep 2024; Participants recruitment failure

P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital of Nanjing Medical University; the First Affiliated Hospital of Nanjing Medical University

P=N/A, N=170, Completed, Xuanwu Hospital, Beijing | N=248 --> 170 | Trial completion date: Dec 2021 --> Jul 2024 | Trial primary completion date: Dec 2021 --> Jul 2024

P3, N=420, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P3, N=600, Active, not recruiting, Rigshospitalet, Denmark | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: Dec 2025 --> May 2026

P4, N=420, Recruiting, Rush University Medical Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2024

P4, N=200, Recruiting, Emory University | Not yet recruiting --> Recruiting

P1, N=134, Recruiting, Oncotherapeutics | Trial primary completion date: Sep 2022 --> Sep 2024

This study shows that the two-drug class combination of ISAdm is an effective and well tolerated treatment option for RRMM patients exhibiting only BP.

The patient was treated with 10% urea cream, 0,25% desoximetasone cream, oral cetirizine 10 mg once daily, oral erythromicin 500 mg four times daily, and oral methylprednisolone 8 mg twice daily for a month along with compression stockings and limb elevation during night hours. Furthermore, she received 10 mg/ml triamcinolone acetonide injection every month...This case emphasizes that a suspicious lesion should always undergo biopsy. Appropriate diagnosis and management can help improving patient life quality immensely.

Oral antihistamines and a gradually reduce course of oral methylprednisolone starting from 32 mg daily and topical mometasone furoate 0,1% cream improved but did not clear his rash. Clinicians should be aware of triptorelin as a culprit of eosinophilic dermatitis. 18 MAY - 20 MAY 2023 POWERED BY M-ANAGE.COM

Ruxolitinib with lenalidomide and dexamethasone shows anti-myeloma effects in vitro and in vivo...Subjects received ruxolitinib twice daily, lenalidomide daily on days 1-21 of a 28-day cycle and methylprednisolone orally every other day...This Phase I trial demonstrates that a JAK inhibitor, ruxolitinib, can overcome refractoriness to lenalidomide and steroids for patients with RRMM. These results represent a promising novel therapeutic approach for treating MM.

The Epstein-Barr virus test showed the patient tested negative for immunoglobulin (Ig)A and IgM, but was positive for IgG. Immunosuppression associated with the treatment for BP may activate a latent HHV-8 infection and induce the development of KS.

The integrin antagonist vedolizumab has the advantage over the standard in this situation, the TNFα antibody infliximab, of causing fewer pulmonary infections...In contrast to CMV-aggravated colitis, the usual therapy with ganciclovir in addition to the steroid is not the first choice. Such patients can particularly benefit from anti-inflammatory therapy with vedolizumab, which has a less pulmonary immunosuppressive effect, which in times of coronavirus Pandemic made sense.

The successful use of the IL-6 receptor antagonist tocilizumab has also been described...The patient had been receiving dabrafenib and trametinib for one month after being treated with pembrolizumab as adjuvant...The administration of paracetamol and an imputed antibiotic therapy with piperacillin / tazobactam did not lead to defever, but to further increasing lymphocytopenia and increasing CRP up to 311.5 mg / L (norm: <3 mg / l)...The intravenous administration of 150 mg prednisolone daily for 4 days led to a prompt defever, normalization of weight and resolution of all other symptoms. The patient tolerated the subsequent change in therapy to vemurafenib / cobimetinib without complications. Due to the increasing combination of therapies in patients with metastatic melanoma, the frequency of CRS can increase and should be included in differential diagnostic considerations for the symptoms mentioned above.

Dapsone was initiated as a steroid sparing agent at 25 mg daily increasing slowly to 75 mg daily as the prednisolone was slowly reduced. The second patient was a 61‐year‐old man with known myelodysplasia...These cases highlight the importance of recognizing acute presentations of NND. They also emphasize the role of dermatologists in ensuring early diagnosis, with consequent avoidance of both unnecessary surgical procedures and the significant morbidity associated with misdiagnosis of NF.

A systemic therapy with methylprednisolone 60 mg/daily and azathioprine 100 mg/daily was initiated, aiming to alleviate the progressively worsening muscle weakness, but proved ineffective. Although it is generally accepted that patients with DM should undergo some type of cancer screening, there is no consensus regarding methods or frequency. New data suggest that blind screening in asymptomatic patients might be of great importance for early diagnosis and treatment of patients with cancer-associated DM.

These results suggest that nM grade of MP potentiates the cytotoxic effect of TET possibly via regulation of NF-κB activation and "G0/G1 to S" phase transition in human T lymphoblastoid leukemia MOLT-4 cells. Combination of TET and MP may provide a new therapeutic strategy for relapsed T-ALL.

HSR to rituximab may be induced by the activation of mast cells and basophils. Desensitization protocols are developed when there is no alternative drug for the underlying condition.

The first patient was treated with the combination of Vemurafenib and Cobimetinib, BRAF and MEK inhibitors, respectively, for a cutaneous melanoma...She was successfully treated with methylprednisolone. The second patient received therapy with Imatinib, tyrosine kinase inhibitor and precursor of the targeted therapy, for a gastrointestinal stromal tumour...DISCUSSION AND  We strengthen the relevance of neuromuscular complications which may occur long after treatment start or in patients receiving not only the latest ICPi but also "older" and apparently better-known targeted therapies. Also in the latter cases, an immune-mediated "off-target" pathogenic mechanism can be hypothesized, and consequences can be life threatening, if not promptly diagnosed and appropriately managed.

Only 3% patients required pericardiocentesis due to tamponade at the time of the initial presentation. The patient's undiagnosed myelodysplastic syndrome may have led to immunosuppression precipitating acute mumps infection that was potentially a costly red herring although it may have augmented the pathological process.

Patient was admitted to the hospital and started on broad-spectrum antibiotics and Osimertinib was held...Osimeritnib induced interstitial lung disease was diagnosed and patient was discharged home on taper dose of prednisone over next several weeks...The diagnosis can be challenging both clinically as well as radiographically as signs and symptoms mimic with other etiologies such as infections. Treatment includes high dose steroids, drug discontinuation, supplemental oxygen and mechanical ventilation in more severe involvement.

Her entire hospital stay included 13 blood transfusions, 4 rounds of monthly cyclophosphamide, high dose methylprednisolone for several weeks, 4 rounds of weekly rituximab, 43 days on HFOV, 57 days on conventional ventilator, and gastrostomy and tracheostomy dependence...Also described is the association of other RAS-associated autoimmune leukoproliferative disorders (KRAS or NRAS mutation) with JMML. To our knowledge there are no documented cases of a patient less than five with severe lupus, presenting with pulmonary alveolar hemorrhage, also known to have a somatic mutation of NRAS gene, which is thought to be less likely to be associated with RASopathy.

Cyclosporine A (CyA; 3mg/kg/d i.v., then 6 mg/kg/d p.o. adjusting for blood levels 200-400 ng/ml) and mycophenolate mofetil (MMF; 15mg/kg two times daily per os) were started on day+5...D+56 aGVHD gr.3: skin, gastrointestinal tract, BM (full resolution on therapy with methylprednisolone 2mg/kg, after the withdrawal of methylprednisolone there was a reversal, in therapy - MMF, Basiliximab; full resolution D+100)...D+343 chronic GVHD: skin, BM, febrile, gastrointestinal, treated with methylprednisolone and Rituximab#4... HLA-haploidentical HSCT with post-transplant high-dose cyclophosphamide is feasible and effective in children with relapse B-lymphoblastic Lymphoma. Reason for a-GVHD and cGVHD in this case was connected with high numbers of transfusions in first line of therapy (not always with leukodepleted products).

Cyclosporine A (CyA; 3mg/kg/d i.v., then 6 mg/kg/d p.o. adjusting for blood levels 200-400 ng/ml) and mycophenolate mofetil (MMF; 15mg/kg two times daily per os) were started on day+5...D+56 aGVHD gr.3: skin, gastrointestinal tract, BM (full resolution on therapy with methylprednisolone 2mg/kg, after the withdrawal of methylprednisolone there was a reversal, in therapy - MMF, Basiliximab; full resolution D+100)...D+343 chronic GVHD: skin, BM, febrile, gastrointestinal, treated with methylprednisolone and Rituximab#4... HLA-haploidentical HSCT with post-transplant high-dose cyclophosphamide is feasible and effective in children with relapse B-lymphoblastic Lymphoma. Reason for a-GVHD and cGVHD in this case was connected with high numbers of transfusions in first line of therapy (not always with leukodepleted products).

Cyclosporine A (CyA; 3mg/kg/d i.v., then 6 mg/kg/d p.o. adjusting for blood levels 200-400 ng/ml) and mycophenolate mofetil (MMF; 15mg/kg two times daily per os) were started on day+5...D+56 aGVHD gr.3: skin, gastrointestinal tract, BM (full resolution on therapy with methylprednisolone 2mg/kg, after the withdrawal of methylprednisolone there was a reversal, in therapy - MMF, Basiliximab; full resolution D+100)...D+343 chronic GVHD: skin, BM, febrile, gastrointestinal, treated with methylprednisolone and Rituximab#4... HLA-haploidentical HSCT with post-transplant high-dose cyclophosphamide is feasible and effective in children with relapse B-lymphoblastic Lymphoma. Reason for a-GVHD and cGVHD in this case was connected with high numbers of transfusions in first line of therapy (not always with leukodepleted products).

The patient was started on cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone...SPTCL may be associated with SLE and the skin findings are often difficult to distinguish between lupus erythematosus panniculitis. SPTCL patients rarely develop hemophagocytic syndrome, and those that do have a poorer prognosis.

ET-1 and IL-6 might exert pro-inflammatory effects in the pathogenesis of NMOSD, whereas IL-10 played an anti-inflammatory role in this process. ET-1 might be a potential biomarker for predicting the severity of NMOSD. However, the serum levels of ET-1 were not correlated with the changes of other cytokines/chemokines in patients with NMOSD. The involvement of ET-1 in the development of NMOSD needs to be further studied.

The symptoms were relieved by discontinuing toripalimab and administering once-daily intravenous methylprednisolone 1 mg/kg. We suggest that this case serves a warning to clinicians of the need to be aware of the possiblilty of toripalimab-induced dermatomyositis. Early recognition and treatment may prevent progression and improve prognosis of this irAE.

Methods During October 2019 and January 2020, Patients were included in our pilot study when they developed rapidly to severe CRS (≥3) in 4 days after CAR T cell infusion, and Tocilizumab (8mg/kg/dose) and Steroids (2 to 15 mg/kg/d methylprednisolone) could not alleviate the symptoms...No adverse effects related to ruxolitinib were observed. Conclusion Our study demonstrated the high efficacy and safety of ruxolitinib in treating steroids resistant CRS during CAR T therapy, especially for patients who had early relapse after allo-HCT and high leukemia burden

We successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining. FoxP3Tregs showed a negative correlation with CD8 and CD4/CD8T cells and a positive correlation with AFP, and VEGF (P<0.05). SRL-based therapy reduces FoxP3Tregs to decrease secreted inhibitory cytokines which may enhancement the viability and number of CD8T cells to exert anti-tumor effects that are mainly mediated through the AKT-mTOR signaling pathway.

Treatment strategy employing intravenous methylprednisolone pulse therapy followed by oral prednisone with slow tapering resulted in an improvement of his symptoms and a sustained remission. Coexistence of MOG-IgG and GFAP-IgG with distinct underlying pathogeneses necessitates the recommendations to screen all recognized pathogenic antibodies against CNS antigens when an autoimmune disease is suspected, since it shows great significance for definite diagnosis of disease and treatment strategy options.

Another batch of rats (subdivided into sham, injury model, AZD8797 and methylprednisolone groups) were used to evaluate locomotive recovery with a Basso Beattie Bresnahan score. The effect of AZD8797 was mediated by suppressing apoptosis, necrosis and inflammatory responses, as assessed by WB/ELISA and morphological examinations. The current study has demonstrated that AZD8797 can effectively block overwhelming inflammation, apoptosis and necrosis after SCI and facilitate early recovery of locomotive function.

To evaluate the effects of exosomes in GIONFH, a dexamethasone-treated or exosome-treated in vitro cell model and a methylprednisolone-treated in vivo rat model were set up. Exosomes are effective at inhibiting osteocyte apoptosis (in MLO-Y4 cells) and at preventing rat GIONFH. These beneficial effects are mediated by the miR-21-PTEN-AKT signalling pathway.